These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17316101)

  • 1. In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 insulin pump.
    Senstius J; Harboe E; Westermann H
    Diabetes Technol Ther; 2007 Feb; 9(1):75-9. PubMed ID: 17316101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro Stability of Biosimilar Insulin Aspart SAR341402 in the Medtronic MiniMed Insulin Pumps.
    Mohnicke M; Blecher A; Beichert K; Bidlingmaier B; Todt EJ; Dette C; Rotthaeuser B; Mukherjee B
    J Pharm Sci; 2023 Apr; 112(4):963-973. PubMed ID: 36521561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in insulin pumps.
    Senstius J; Poulsen C; Hvass A
    Diabetes Technol Ther; 2007 Dec; 9(6):517-21. PubMed ID: 18034606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro stability of insulin lispro in continuous subcutaneous insulin infusion.
    DeFelippis MR; Bell MA; Heyob JA; Storms SM
    Diabetes Technol Ther; 2006 Jun; 8(3):358-68. PubMed ID: 16800757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of insulin lispro in insulin infusion systems.
    Lougheed WD; Zinman B; Strack TR; Janis LJ; Weymouth AB; Bernstein EA; Korbas AM; Frank BH
    Diabetes Care; 1997 Jul; 20(7):1061-5. PubMed ID: 9203437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 14-day in vitro chemical stability of insulin lispro in the MiniMed Paradigm pump.
    Sharrow SD; Glass LC; Dobbins MA
    Diabetes Technol Ther; 2012 Mar; 14(3):264-70. PubMed ID: 22107252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of pharmacokinetic properties, physicochemical stability, and pump compatibility of 3 rapid-acting insulin analogues-aspart, lispro, and glulisine.
    Bode BW
    Endocr Pract; 2011; 17(2):271-80. PubMed ID: 21134878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Compatibility of insulin Lispro, Aspart, and Glulisine with the Solo MicroPump, a novel miniature insulin pump.
    Senesh G; Bushi D; Neta A; Yodfat O
    J Diabetes Sci Technol; 2010 Jan; 4(1):104-10. PubMed ID: 20167173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of insulin catheter wear-time on subcutaneous adipose tissue blood flow and insulin absorption in humans.
    Clausen TS; Kaastrup P; Stallknecht B
    Diabetes Technol Ther; 2009 Sep; 11(9):575-80. PubMed ID: 19764836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Precipitation of insulin aspart and insulin glulisine products used for continuous subcutaneous insulin infusion.
    Poulsen C; Langkjaer L; Worsøe C
    Diabetes Technol Ther; 2007 Feb; 9(1):26-35. PubMed ID: 17316095
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of phenol and meta-cresol depletion on insulin analog stability at physiological temperature.
    Teska BM; Alarcón J; Pettis RJ; Randolph TW; Carpenter JF
    J Pharm Sci; 2014 Aug; 103(8):2255-67. PubMed ID: 24909933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability and performance of rapid-acting insulin analogs used for continuous subcutaneous insulin infusion: a systematic review.
    Kerr D; Wizemann E; Senstius J; Zacho M; Ampudia-Blasco FJ
    J Diabetes Sci Technol; 2013 Nov; 7(6):1595-606. PubMed ID: 24351186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the pharmacokinetics of three concentrations of insulin aspart during continuous subcutaneous insulin infusion (CSII) in a pig model.
    Petersen SB; Nielsen FS; Ribel U; Sturis J; Skyggebjerg O
    J Pharm Pharmacol; 2013 Feb; 65(2):230-5. PubMed ID: 23278690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The comparison of insulin aspart and human soluble insulin used in insulin pump therapy in newly diagnosed type 2 diabetic patients].
    Li YB; Liu J; Liao ZH; Liao Y; Deng WP; Weng JP
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2472-6. PubMed ID: 16321271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of local skin temperature and choice of insulin analog on catheter occlusion rates during continuous insulin infusion: an exploratory study.
    Naik S; Kerr D; Begley J; Morton J
    Diabetes Technol Ther; 2012 Nov; 14(11):1018-22. PubMed ID: 23101952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T
    Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigation of the Physico-Chemical Properties that Enable Co-Formulation of Basal Insulin Degludec with Fast-Acting Insulin Aspart.
    Havelund S; Ribel U; Hubálek F; Hoeg-Jensen T; Wahlund PO; Jonassen I
    Pharm Res; 2015 Jul; 32(7):2250-8. PubMed ID: 25563978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.